349 results on '"Senitzer, David"'
Search Results
52. 44-OR
53. 32-OR
54. Protective effect of the KIR2DS1 gene in atopic dermatitis
55. Detection and preliminary characterization of CD8+T lymphocytes specific for Wilms’ tumor antigen in patients with non-Hodgkin lymphoma
56. Both the nature of KIR3DL1 alleles and the KIR3DL1/S1 allele combination affect the KIR3DL1 NK‐cell repertoire in the French population
57. Influence of Drug Absorption, Distribution, Metabolism, and Excretion (ADME) Variants on Sirolimus Blood Levels in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation
58. Phase I Trial of Escalated Doses of Targeted Marrow Radiation Delivered by Tomotherapy Combined with Etoposide and Cyclophosphamide; An Allogeneic HCT Preparative Regimen for Patients with Advanced Leukemia
59. Genetic Susceptibility to Anthracycline-Related Congestive Heart Failure (CHF) in Survivors of Hematopoietic Cell Transplantation (HCT)
60. KIR2DS2 and KIR2DS4 promoter hypomethylation patterns in patients undergoing hematopoietic cell transplantation (HCT)
61. 110-P
62. 91-P
63. 125-P
64. 28-OR
65. 104-P
66. Killer Immunoglobulin-like Receptor (KIR) and HLA Genotypes Affect the Outcome of Allogeneic Kidney Transplantation
67. Can immune-related genotypes illuminate the immunopathogenesis of cytomegalovirus disease in human immunodeficiency virus–infected patients?
68. Detection and Characterization of Antigen-Driven CD8+ T Lymphocytes Specific for Wilms' Tumor Antigen in Patients with Non-Hodgkin Lymphoma
69. Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control
70. 22-OR: The Treg MLR: Monitoring of Donor-Specific Immunoregulation in HLA Identical Renal Transplants With Donor Hematopoietic Stem Cell (DHSC) Infusions
71. 26-OR: Leukemic Cells Can Influence QPCR Results: A Case Study
72. Does the KIR2DS5 Gene Protect from Some Human Diseases?
73. Role of killer cell immunoglobulin-like receptor gene content and human leukocyte antigen–C group in susceptibility to human T-lymphotropic virus 1–associated myelopathy/tropical spastic paraparesis in Peru
74. Improved Outcome After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RI-HCT) for Myelodysplastic Syndrome (MDS) Using Tacrolimus/Sirolimus-Based Gvhd Prophylaxis.
75. 13-W: Do anti-HLA antibodies impact hematopoietic stem cell transplantation (HSCT)?
76. 216-P: Defining new HLA-B*15 alleles
77. Killer immunoglobulin‐like receptor ligand HLA‐Bw4 protects against multiple sclerosis
78. Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone
79. Thrombotic Microangiopathy with Tacrolimus/Sirolimus-Based GVHD Prophylaxis Regimen in Patients Undergoing Hematopoietic Stem Cell Transplant from a Matched Unrelated Donor
80. 109-P: Increased incidence of HLA antibodies (Class I/II) in hematopoietic cell transplant (HCT) candidates detected by a solid phase assay
81. 82-P: A new HLA-B allele sharing sequences with B*4006 and B*0702 in an Asian Indian donor
82. 116-P: Chimerism detection by real-time PCR vs STR PCR
83. Impact of Graft Cell Dose on Transplant Outcomes following Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplantation: Higher CD34+ Cell Doses Are Associated with Decreased Relapse Rates
84. Chemokine Receptor Gene Polymorphisms and Severity of Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation from Sibling Donors.
85. 59-W: Loss of HLA and STR alleles observed in a patient during blast crisis
86. Particular genetic variants of ligands for natural killer cell receptors may contribute to the HLA associated risk of primary sclerosing cholangitis
87. Common and Well-Documented HLA Alleles
88. The Use of Sirolimus Combined with Tacrolimus and Low-Dose Methotrexate Is Effective in Preventing Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation.
89. Tacrolimus and Sirolimus as GVHD Prophylaxis for HLA-MRD Allogeneic HCT Conditioned with 3 Regimens: Toxicity and Efficacy in 70 Patients.
90. 19-W
91. 33-OR
92. Evidence of Donor-Derived Hematologic Malignancies after Hematopoietic Stem Cell Transplantation
93. Transplant CD34+ Cell Dose Affects Outcomes Following Allogeneic Peripheral Blood Stem Cell Transplantation from a Matched Unrelated Donor.
94. The case of a homozygous heterozygote
95. Evidence of Donor Derived Malignancies Following Hematopoietic Stem Cell Transplantation.
96. Experiences of the stemcyte umbilical cord bank
97. Monitoring cell subset engraftment on the ABI with the ABI identifiler kit
98. A simplified KIR gene-typing method by multiplex PCR-SSP
99. The detection and quantitation of IgH monoclonality in bone marrow transplant recipients
100. Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.